Lv5
870 积分 2024-12-05 加入
Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR Mutant Non-Small Cell Lung Cancer
14天前
已完结
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
23天前
已完结
Discovery and development of Krazati (adagrasib/MRTX849), a potent, selective, orally bioavailable, covalent KRASG12C(OFF) inhibitor
23天前
已完结
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
23天前
已完结
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
23天前
已完结
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
1个月前
已完结
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
1个月前
已完结
Synthetic lethality as an engine for cancer drug target discovery
1个月前
已完结
Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity
2个月前
已完结
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
2个月前
已完结
皖公网安备34019202002308
